Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 251 matching trials from the live ClinicalTrials.gov search.
Conditions
Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Moderately Reduced Ejection Fraction, Diastolic Heart Failure
Interventions
Cardiac Contractility Modulation Therapy via OPTIMIZER™ Smart Mini System, OPTIMIZER™ Smart Mini System
Device
Lead sponsor
Impulse Dynamics
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
105
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
AZD4831, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
21
States / cities
Alexander City, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more
Conditions
Atrial Fibrillation, Heart Failure With Normal Ejection Fraction
Interventions
Pulmonary Vein Isolation
Procedure
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years to 90 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Fairfax, Virginia
Conditions
Heart Failure
Interventions
Rheos® system
Device
Lead sponsor
CVRx, Inc.
Industry
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
22
States / cities
Mobile, Alabama • Inglewood, California • Los Angeles, California + 18 more
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2
Interventions
Semaglutide, Placebo (Semaglutide)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
54
States / cities
Fairhope, Alabama • Mobile, Alabama • Beverly Hills, California + 47 more
Conditions
Atrial Fibrillation, Heart Failure, Diastolic Heart Failure
Interventions
Catheter ablation, Rate or Rhythm control antiarrhythmic drugs for atrial fibrillation, Insertion of CardioMems Hemodynamic monitor, Empiric heart failure drug therapy
Device · Drug
Lead sponsor
Electrophysiology Research Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
7
States / cities
Flagstaff, Arizona • Jonesboro, Arkansas • Littleton, Colorado + 4 more
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
0.9% Sodium Chloride, Furosemide 40 mg
Drug
Lead sponsor
Adhish Agarwal
Other
Eligibility
21 Years to 80 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

The Effect of Adiposity on Muscle and Microvascular Function in HFpEF

NCT06930495
Conditions
Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
Weight loss SOC Treatment with second generation anti-diabetic medications
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
Verinurad, Allopurinol, Placebo for verinurad, Placebo for allopurinol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 130 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Granada Hills, California • Northridge, California • Torrance, California + 5 more
Conditions
Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
Interventions
Maridebart cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
5,056 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
121
States / cities
Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 107 more
Conditions
Diabetes Mellitus, Type 2, Heart Failure With Preserved Ejection Fraction (HFPEF)
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years and older
Enrollment
11,265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Not applicable Interventional

Resistance Training in HFpEF

NCT02435667
Conditions
Heart Failure Preserved Ejection Fraction
Interventions
Resistance Exercise Training, DEXA bone scan, Cardiopulmonary Max Exercise Test, Quality of Life Questionnaire, Submaximal Exercise Test, Blood Draw
Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Completed Not applicable Interventional Results available

REALIsM-HF Pilot Study

NCT03507439
Conditions
Heart Failure
Interventions
AVIVO Mobile Patient Management (MPM) System, VitalPatch biosensor, DynaPort Move Monitor
Device
Lead sponsor
Bayer
Industry
Eligibility
45 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Recruiting No phase listed Observational Accepts healthy volunteers

US Benchmarking Clinical Study

NCT07215715
Conditions
HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy, Cardiac Amyloidosis
Interventions
Not listed
Lead sponsor
eMyosound SAS
Industry
Eligibility
60 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Diabetes Mellitus, Heart Failure
Interventions
Tc99m-Maraciclatide
Drug
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Princeton, New Jersey
Conditions
Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions
DASH Diet, Usual diet
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
60 Years to 74 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Heart Failure With Normal Ejection Fraction, Obesity
Interventions
Increasing daily unsaturated fatty acid consumption
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Heart Failure, Diastolic
Interventions
Furosemide, Dopamine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
sacubitril/valsartan, Enalapril, Valsartan, Placebo to match sacubitril/valsartan, Placebo to match enalapril, Placebo to match valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
2,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Andalusia, Alabama • Mobile, Alabama • Beverly Hills, California + 29 more
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
Potassium Nitrate, Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside, Potassium Chloride
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
Interventions
TX000045- Dose A, TX000045- Dose B, Placebo
Drug
Lead sponsor
Tectonic Therapeutic
Industry
Eligibility
18 Years to 83 Years
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • San Francisco, California + 21 more
Conditions
Heart Failure With Preserved Ejection Fraction, Iron Deficiency
Interventions
Ferric derisomaltose, Placebo (normal saline)
Drug
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Conversations Helpful for Awareness of Illness Trajectory (CHAT) Intervention, Standard of Care (SOC)
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
60 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Conditions
Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions
Semaglutide, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
58,387 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Boston, Massachusetts